Patients with the RET M918T mutation are in the “highest risk” (ATA-HST) category for developing aggressive MTC, whereas patients with A883F belong to ATA-H category; Of these, ~50% of MEN2B patients develop PHEO (2, 4, 32). Here, RET is linked to medullary thyroid gland carcinoma.